DK2621945T3 - Nd2-peptider og fremgangsmåder til behandling af neurologisk sygdom - Google Patents

Nd2-peptider og fremgangsmåder til behandling af neurologisk sygdom Download PDF

Info

Publication number
DK2621945T3
DK2621945T3 DK11833072.9T DK11833072T DK2621945T3 DK 2621945 T3 DK2621945 T3 DK 2621945T3 DK 11833072 T DK11833072 T DK 11833072T DK 2621945 T3 DK2621945 T3 DK 2621945T3
Authority
DK
Denmark
Prior art keywords
peptide
pain
src
tat
peptides
Prior art date
Application number
DK11833072.9T
Other languages
English (en)
Inventor
Michael Tymianski
Rongwen Li
Jonathan David Garman
Original Assignee
Nono Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc filed Critical Nono Inc
Application granted granted Critical
Publication of DK2621945T3 publication Critical patent/DK2621945T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/05—Oxidoreductases acting on NADH or NADPH (1.6) with a quinone or similar compound as acceptor (1.6.5)
    • C12Y106/05003—NADH dehydrogenase (ubiquinone) (1.6.5.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (15)

1. ND2-peptid med ikke mere end 20 rester, der er identiske med resterne ifølge SEQ ID NO: 60, hvor ND2-peptidet indbefatter resterne 310-321 ifølge SEQ ID NO: 60 og hæmmer ND2-interaktion med Src.
2. ND2-peptid ifølge krav 1, der er ND2 307-321 (SEQ ID NO: 22) eller ND2 310-321 (SEQ ID NO: 23).
3. ND2-peptid ifølge krav 1, hvor ND2-peptidet består af aminosyrerne 310-321 ifølge SEQ ID NO: 60.
4. ND2-peptid ifølge et hvilket som helst foregående krav, hvor ND2-peptidet er myristoyleret ved dets N-terminus.
5. ND2-peptid ifølge et hvilket som helst foregående krav, hvor ND2-peptidet er bundet til et internaliseringspeptid som et kimærisk peptid.
6. ND2-peptid ifølge krav 5, hvor ND2-peptidet er bundet til intemaliseringspeptidet som et fusionspeptid.
7. ND2-peptid ifølge krav 5 eller 6, hvor intemaliseringspeptidet er bundet til ND2-peptidets N-terminus.
8. ND2-peptid ifølge et hvilket som helst af kravene 5 til 7, hvor intemaliseringspeptidet indbefatter mindst 5 arginin- eller lysinrester og har en samlet længde på 9-15 aminosyrer.
9. ND2-peptid ifølge et hvilket som helst af kravene 5 til 8, hvor intemaliseringspeptidet er et Tat-peptid.
10. ND2-peptid ifølge et hvilket som helst af kravene 5 til 9, hvor intemaliseringspeptidet er RRRQRRKKRGY.
11. ND2-peptid ifølge et hvilket som helst foregående krav, til anvendelse i behandling eller til at bevirke profylakse af en neurologisk sygdom eller forstyrrelse, eventuelt hvor den neurologiske sygdom eller forstyrrelse er apopleksi, traumatisk CNS-læsion, epilepsi, angst eller en neurodegenerativ sygdom.
12. ND2-peptid til anvendelse ifølge krav 11, hvor den neurologiske sygdom eller forstyrrelse er apopleksi.
13. ND2-peptid ifølge et hvilket som helst af kravene 1-10 til anvendelse i behandling eller til at bevirke profylakse af smerte, eventuelt hvor smerten er neuropatisk, fysiologisk eller inflammatorisk smerte.
14. ND2-peptid til anvendelse ifølge krav 13, hvor smerten er neuropatisk smerte.
15. ND2-peptid ifølge et hvilket som helst af kravene 1-10 til anvendelse i behandling eller til at bevirke profylakse af cancer.
DK11833072.9T 2010-09-28 2011-09-28 Nd2-peptider og fremgangsmåder til behandling af neurologisk sygdom DK2621945T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38743910P 2010-09-28 2010-09-28
PCT/US2011/053764 WO2012050921A2 (en) 2010-09-28 2011-09-28 Nd2 peptides and methods of treating neurological disease

Publications (1)

Publication Number Publication Date
DK2621945T3 true DK2621945T3 (da) 2018-05-22

Family

ID=45938878

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11833072.9T DK2621945T3 (da) 2010-09-28 2011-09-28 Nd2-peptider og fremgangsmåder til behandling af neurologisk sygdom

Country Status (15)

Country Link
US (1) US9073976B2 (da)
EP (1) EP2621945B1 (da)
JP (1) JP6073230B2 (da)
KR (1) KR101893473B1 (da)
CN (1) CN103282379B (da)
AU (1) AU2011314074B2 (da)
BR (1) BR112013007557A2 (da)
CA (1) CA2812948C (da)
DK (1) DK2621945T3 (da)
IL (1) IL225464B (da)
MX (1) MX343366B (da)
RU (1) RU2607033C2 (da)
SG (1) SG189104A1 (da)
UA (1) UA114592C2 (da)
WO (1) WO2012050921A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661126B (zh) * 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
CN109072242A (zh) * 2016-02-23 2018-12-21 科罗拉多州立大学董事会法人团体 用于治疗神经损伤的基于肽的方法
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CN112679595B (zh) * 2020-04-10 2022-11-01 南京市儿童医院 脑源肽或融合肽在新生儿缺氧缺血性脑损伤药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007832A1 (en) * 1997-08-12 1999-02-18 Bristol-Myers Squibb Company Kcnq potassium channels and methods of modulating same
WO2000056880A1 (en) 1999-03-19 2000-09-28 Human Genome Sciences, Inc. 50 human secreted proteins
ME00502B (me) * 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
AU2003262642B2 (en) * 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1551424B1 (en) * 2002-09-04 2015-07-01 Arrowhead Research Corporation Treatment of chronic neuropathic pain by admistration of dsrna
US8003609B2 (en) 2004-03-30 2011-08-23 The Hospital For Sick Children Method for ameliorating pain by modification of NMDA receptors through inhibition of Src
US7425540B2 (en) 2004-03-30 2008-09-16 The Hospital For Sick Children Method for modification of NMDA receptors through inhibition of Src
AU2006261342B2 (en) * 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
DK2120987T3 (da) * 2007-03-02 2014-02-24 Nono Inc Behandling af slagtilfælde og andre sygdomme uden at hæmme N-type calciumkanaler

Also Published As

Publication number Publication date
WO2012050921A2 (en) 2012-04-19
MX343366B (es) 2016-11-01
CN103282379A (zh) 2013-09-04
BR112013007557A2 (pt) 2021-05-11
AU2011314074A1 (en) 2013-05-09
RU2013119830A (ru) 2014-11-10
JP6073230B2 (ja) 2017-02-01
CN103282379B (zh) 2016-01-06
CA2812948A1 (en) 2012-04-19
AU2011314074B2 (en) 2015-11-12
KR20140048070A (ko) 2014-04-23
UA114592C2 (uk) 2017-07-10
RU2607033C2 (ru) 2017-01-10
US9073976B2 (en) 2015-07-07
JP2014505655A (ja) 2014-03-06
US20140274906A1 (en) 2014-09-18
MX2013003330A (es) 2013-09-26
EP2621945B1 (en) 2018-04-11
WO2012050921A3 (en) 2012-07-05
IL225464B (en) 2018-03-29
EP2621945A2 (en) 2013-08-07
IL225464A0 (en) 2013-06-27
KR101893473B1 (ko) 2018-08-30
EP2621945A4 (en) 2014-05-07
SG189104A1 (en) 2013-05-31
CA2812948C (en) 2019-01-22

Similar Documents

Publication Publication Date Title
AU2010259986B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
JP2019501210A (ja) 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
US9073976B2 (en) ND2 peptides and methods of treating neurological disease
JP2024113090A (ja) 神経可塑性を誘導するための方法および組成物
JP5336384B2 (ja) Ｍｎｔｆペプチドおよびその類似体を用いて神経細胞障害を治療する方法
HK1187931A (en) Nd2 peptides and methods of treating neurological disease
HK1187931B (en) Nd2 peptides and methods of treating neurological disease
WO2016090495A1 (en) TARGETED α-L-IDURONIDASE CONJUGATES AND USES THEREOF